Evommune, Inc. (EVMN) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Evommune, Inc. is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of May 5, 2026, there were 36,018,372 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $3.0 million |
| Net Loss | $(21.7) million | $(14.6) million |
| Net Loss Per Share (Basic/Diluted) | $(0.64) | $(9.48) |
| Operating Expenses | $24.0 million | $18.0 million |
| Cash, Cash Equivalents, and Investments | $307.0 million | $172.6 million (investments only) + $5.7M cash |
| Accumulated Deficit | $(242.8) million | $(166.8) million |
Liquidity: As of March 31, 2026, the company held $48.3 million in cash and cash equivalents and $258.7 million in short-term and long-term investments. Management expects these funds to support operations for at least twelve months from the filing date.
Material Changes vs. Prior Period
- Revenue: Revenue decreased by 100% to $0, compared to $3.0 million in Q1 2025. The prior period revenue was a non-recurring license recognition from the Maruho Japan Agreement.
- Operating Expenses: Total operating expenses increased by 33% ($5.9 million) to $24.0 million.
- R&D Expenses: Increased 21% to $17.3 million, driven by higher clinical trial costs for EVO756 and discovery research, partially offset by lower EVO301 costs.
- G&A Expenses: Increased 81% to $6.6 million, primarily due to a $1.9 million increase in stock-based compensation and higher public company operational costs.
- Financing Activity: In February 2026, the company completed a private placement, issuing 4,494,279 shares at $27.88 per share, raising net proceeds of $117.2 million.
- Investing Activity: Net cash used in investing activities was $85.4 million, primarily due to $108.8 million in purchases of investments.
Outlook, Risks, and Management Commentary
- Product Pipeline:
- EVO756: Phase 2b trials in Chronic Spontaneous Urticaria (CSU) and Atopic Dermatitis (AD) are ongoing. Initial CSU results expected in June 2026; AD results in Q3 2026. A Phase 2b trial for migraine is planned for mid-2026.
- EVO301: Manufacturing for a high-concentration subcutaneous formulation has begun. A Phase 2b trial is planned for mid-2027.
- Capital Requirements: The company expects to continue incurring significant losses. Future funding will be required to advance clinical trials and operations. Sources may include equity offerings, debt, or collaborations.
- Risks: Key risks include the failure of clinical trials, inability to obtain regulatory approval, dependence on third-party manufacturers, and the need for additional capital. The company maintains a full valuation allowance against net deferred tax assets due to cumulative losses.
- Lease Commitments: A new 63-month lease for Palo Alto office space commenced in March 2026, with annual payments of approximately $1.5 million for the first three years.
Investor Verification Checklist
- Verify the timeline and enrollment status of the EVO756 Phase 2b trials in CSU and AD, with results expected in mid-to-late 2026.
- Confirm the burn rate and runway based on the $307 million cash position versus the $21.7 million quarterly net loss.
- Review the terms of the February 2026 private placement and any potential dilution from future equity raises.
- Monitor the status of the AprilBio license agreement milestones and associated R&D expenses.
- Assess the impact of the new Palo Alto lease on future fixed operating costs.